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ABSTRACT 49 
Mixed adeno-neuroendocrine carcinomas (MANECs) are composed of a poorly differentiated 50 
neuroendocrine carcinoma (NEC) and a non-neuroendocrine (non-NEC) neoplastic epithelial 51 
component, each representing at least 30% of the tumor. At present, prognostic factors for 52 
MANECs remain largely unexplored. We investigated the clinical-pathologic features of a 53 
large multicenter series of digestive system MANECs. 54 
Surgical specimens of 200 MANEC candidates were centrally reviewed; diagnosis was 55 
confirmed in 160 cases. While morphology, proliferation [mitotic count (MC), Ki67 index] 56 
and immunophenotype (p53, SSTR2a, beta-Catenin, Bcl-2, p16, Rb1, ALDH, Mismatch Repair 57 
proteins, CD117) were investigated separately in both components, genomic (TP53, 58 
KRAS,BRAF) alterations were searched for on the entire tumor. Data were correlated with 59 
overall survival (OS).  60 
MANEC sites were: 92 colorectal, 44 gastro-esophageal and 24 pancreato-biliary. Median OS 61 
was 13.2 months. After adjustment for primary site, Ki67 index of the NEC component (but 62 
not of the non-NEC component) was the most powerful prognostic marker. At multivariable 63 
analysis, patients with Ki67 ≥55% had an 8-fold risk of death [Hazard ratio (HR) 7.83; 95% 64 
confidence interval (CI) 4.17-14.7; p<0.0001] and a median OS of 12.2 months compared to 65 
those with Ki67<55% (median OS 40.5 months). MC (HR 1.51; 95% CI 1.03-2.20, p=0.04) was 66 
a weaker prognostic index. Colorectal primary site (HR 1.60; 95% CI 1.11-2.32; p=0.01) was 67 
significantly associated with poorer survival. No single immunomarker, in either component, 68 
was statistically significant. This retrospective analysis of a large series of digestive system 69 
MANECs), showed that the NEC component, particularly its Ki-67 index, was the main 70 
prognostic driver. 71 
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INTRODUCTION 73 
The coexistence of neuroendocrine and non-neuroendocrine components in the same 74 
neoplasm is a rare but well known phenomenon in digestive system tumors. The 2010 World 75 
Health Organization (WHO) classification of tumors of the digestive system proposed the 76 
term “mixed adeno-neuroendocrine carcinoma” (MANEC) to define these cancers in which, 77 
by definition, each component represents at least 30% of the tumor mass (Bosman F 2010). 78 
The pathogenesis of MANECs is still unclear, and different hypotheses have been proposed 79 
to explain their biphasic morphology. Molecular investigations have suggested a multistep 80 
progression from a common precursor lesion. Indeed, the higher frequency of chromosomal 81 
and gene abnormalities found in the neuroendocrine component compared to the non-82 
neuroendocrine component suggests that progression from a non-neuroendocrine towards 83 
a neuroendocrine cell phenotype, and not vice-versa, is more frequent (Furlan, et al. 2003; 84 
Huang, et al. 2002; Jesinghaus, et al. 2017; Kim, et al. 2002; Paniz Mondolfi, et al. 2011; 85 
Scardoni, et al. 2014; Volante, et al. 2015; Vortmeyer, et al. 1997; Woischke, et al. 2017). 86 
The clinical behavior of MANECs is generally aggressive, however prognostic markers 87 
predictive of MANEC outcome have not been definitively validated to date. Whether 88 
prognostic markers of poorly differentiated neuroendocrine carcinomas (NECs), such as 89 
proliferation, CD117 expression and microsatellite instability, have the same prognostic 90 
relevance in MANECs is, as yet, unknown. Moreover, considering the peculiar morphologic 91 
characteristics of MANECs, additional specific parameters may be prognostically important, 92 
including the percentage and type of different tumor components, tumor site, morphologic 93 
features (i.e. tumor cell budding, vascular and perineural infiltration, intra- and peri-tumoral 94 
lymphoid infiltration), type of tumor component in nodal or distant metastases, 95 
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immunophenotype and molecular profile. To the best of our knowledge, these diverse 96 
characteristics have never been fully investigated in a large series of digestive MANECs. 97 
In this retrospective multicenter study, we collected a large series of MANECs and we 98 
extensively investigated clinical, morphologic, immunohistochemical and molecular features 99 
in order to characterize the different tumor components and to search for parameters useful 100 
in  prognostic stratification. 101 
 102 
MATERIALS AND METHODS  103 
Case selection and study design 104 
Between 1995 and 2015, the surgical pathology and clinical databases of eleven Italian 105 
Institutions were retrospectively searched and patients with one of the following diagnoses 106 
at histology report sign out were selected: “mixed exocrine-neuroendocrine carcinoma”, 107 
“adenoneuroendocrine carcinoma (MANEC)”, “composite glandular endocrine carcinoma” 108 
“carcinoma with neuroendocrine differentiation”, “amphicrine/combined, carcinoma or 109 
tumor”, “mixed adenocarcinoma and neuroendocrine carcinoma”. Exclusion criteria were: i) 110 
cases with only biopsy material available; ii) cases with either NEC or non-NEC component 111 
<30%; iii) cases in which the neuroendocrine component was well differentiated (as 112 
discussed by  La Rosa, et al. 2012; and Ohike 2017); iv) patients who underwent neoadjuvant 113 
chemotherapy. 114 
A total of 200 candidate cases were identified. Patients’ charts and tumor morphology were 115 
carefully revised, first by the pathologist of the case-proposing hospital and then by a panel 116 
of seven expert pathologists (MM, AP, PS, AV, LA, SLR, and CC) using a multihead 117 
microscope. During panel consensus meetings, the original diagnosis was reviewed and 118 
further workup was carried out whenever panelists disagreed or quantitative evaluations 119 
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approached cut-off values For qualitative parameters a majority decision was adopted, while 120 
for quantitative evaluations the mean of values obtained by the individual panelists was 121 
taken as final. MANEC identification, quantitative evaluation of the NEC versus non-NEC 122 
components, and sub-type characterization as collision or combined were based on parallel 123 
investigation of at least two consecutive sections from representative blocks, stained with 124 
hematoxylin-eosin and synaptophysin, respectively. Ki67 proliferative rate (or other 125 
histochemical parameters investigated) was assessed on a third consecutive section. The 126 
identification of an amphicrine component was based on finding synaptophysin reactivity 127 
within the cytoplasm of cells also showing signet ring or gland-forming patterns after alcian 128 
blue counterstaining of the same section or with the help of an adjacent section stained with 129 
PAS and alcian blue. In the end, 160 cases met all the above criteria and were enrolled in the 130 
study. 131 
Morphologic analysis (Table 1) considered: a) assessment of the percentage of NEC and non-132 
NEC components; b) morphology of non-NEC component: adenoma, adenocarcinoma, 133 
mucinous carcinoma, signet-ring carcinoma, squamous cell carcinoma and acinar cell 134 
carcinoma (only in pancreatic site) (La Rosa et al. 2012a); c) morphology of NEC component: 135 
small cell or large cell according to WHO 2010 (Bosman F 2010; Rindi G 2010); d) necrosis in 136 
the NEC component; e) Ki67 index was defined using the MIB antibody as a percentage of 137 
500-2000 cells counted in areas of strongest nuclear labelling (“hot spots”)(Rindi G 2010); f) 138 
mitotic count (MC) was evaluated in at least 10 HPF (10 HPF=2mm
2
)(Rindi G 2010); g) 139 
quantitative assessment of NEC, non-NEC or mixed type components in lymph node 140 
metastases and/or in distant metastases; h) tumor staging according to the Union for 141 
International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) 8
th
 edition 142 
(Amin2017); i) lymphovascular invasion (evaluated on both hematoxylin-eosin (H&E) and/or 143 
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CD31-stained sections); l) perineural invasion; m) intra and/or peritumoral lymphocytic 144 
infiltration; n) prevalent tumor component (NEC, non-NEC or mixed type) on the deep 145 
invasive front; o) type of combination of the NEC and non-NEC component: collision when 146 
the two components were clearly demarcated, combined when they were intimately 147 
admixed, and amphicrine/combined, when the same cells displayed both neuroendocrine 148 
and non-neuroendocrine phenotype, (as  a rule this was observed in a combined histological 149 
background; p) tumor budding defined according to the International Tumor Budding 150 
Consensus Conference 2016 (ITBCC) (Lugli, et al. 2017). 151 
The histochemical and immunohistochemical (IHC) study (Supplementary table 1) included: 152 
a) Alcian Blue-Periodic Acid-Schiff (PAS) to better define mucin production in the non-NEC 153 
epithelial neoplastic component; b) synaptophysin and chromogranin A (general 154 
neuroendocrine immunomarkers) in order to confirm the presence and extent of the NEC 155 
component (Figure 1B); c) Ki67 staining evaluated in both NEC and non-NEC components 156 
(Bosman F 2010; Rindi G 2010); d) IHC assessment and evaluation in both components of 157 
several markers including p53, Rb1, p16, Bcl-2, Beta-Catenin, aldehyde dehydrogenase 158 
(ALDH), CDX2, thyroid transcription factor-1 (TTF1), mismatch repair (MMR) proteins, CD117 159 
and somatostatin receptor 2A (SSTR2A) using the antibodies listed in Supplementary Table 2. 160 
With the exception of p53 and SSTR2A, all markers were considered positive regardless of 161 
the number of positive cells. p53 was considered positive when ≥30% of cells were positive 162 
(Ali, et al. 2017); SSTR2A was assessed according to Volante et al. (positive: 2+, 3+; negative: 163 
0, 1+ score) (Volante, et al. 2007). MMR deficiency was established according to the criteria 164 
reported by Chiaravalli et al. (Chiaravalli, et al. 2001). 165 
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Data concerning mutations (Table 1) of KRAS (codons 12 and 13), BRAF (codon 600)  and 166 
TP53 (exons 5 to 8) were extracted from investigations performed for therapy decision 167 
making, either by PCR pyrosequencig as described by (Sahnane, et al. 2015)  or by Next 168 
Generation Sequencing analysis (NGS) as detailed by (Meazza, et al. 2016).  169 
 170 
This study was performed according to the clinical standards of the 1975 and 1983 171 
Declaration of Helsinki and was approved by the Ethical Committee of Fondazione IRCCS 172 
Istituto Nazionale dei Tumori, Milan, Italy (n° INT 21/16). 173 
Evaluation of proliferative cut-offs 174 
We searched for prognostically relevant cut-offs of Ki67 and MC. The results of our 175 
exploratory analysis are shown in Supplementary Figure 1. 176 
Statistical analysis 177 
Data were analyzed by descriptive statistics. Differences in frequencies were assessed with 178 
the Chi-square or the Fisher exact test. The primary study endpoint was the correlation of 179 
overall survival (OS) with primary tumor site, tumor stage, NEC subtype (large or small cell), 180 
non-NEC histotype, MANEC type (collision, combined, amphicrine/combined), percentage of 181 
NEC and non-NEC components (evaluated on: whole neoplasm, invasive front, lymph nodes 182 
and/or distant metastases), lymphocytic intratumoral and peritumoral infiltrate, 183 
angioinvasion, perineural invasion and necrosis in the NEC component. The following 184 
parameters were separately evaluated in NEC and non-NEC components: MC, Ki67, MMR 185 
deficiency, Bcl-2, Rb1, p16, p53, TTF1, CDX2, CD117, ALDH, Beta-Catenin and SSTR2a. 186 
OS was assessed from the time of diagnosis to the time of death or last follow-up. Survival 187 
curves were drawn according to the Kaplan-Meier method, and difference between groups 188 
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was assessed with the log rank test. The proportions of patients surviving at different time 189 
points are presented with respective 95% Confidence Interval (CI). Univariable and 190 
multivariable Cox proportional hazards regression analysis was used to assess the prognostic 191 
significance of various clinical and histopathologic characteristics. Data analysis was 192 
performed using the SAS software (version 9.4, Cary NC, USA). All tests were two-sided and 193 
p-values <0.05 were considered statistically significant. 194 
 195 
RESULTS 196 
Clinicopathologic features 197 
Table 1 and Figure 1 summarize the main clinicopathologic features of the 160 patients 198 
enrolled in the study. The series comprised more males than females (72.5% vs 27.5%) and 199 
this difference was statistically significant and was maintained across tumor sites (p=0.04). 200 
Most patients (74.4%) had Stage IIIB disease. MANECs were more frequently colorectal 201 
(n=92, 57.5%), with a prevalence in the right colon (64 cases) versus the left colon (10 cases) 202 
and rectum (18 cases), followed by gastro-esophageal (n=44, 27.5%) locations, with a 203 
prevalence (32 cases) for stomach, versus cardio-esophageal junction (9 cases) and 204 
esophageal tumors (3 cases). Finally pancreato-biliary locations were the least common 205 
(n=24, 15.0%), the majority of these were pancreatic tumors (14 cases) compared to 206 
gallbladder (7 cases) or extrahepatic biliary tract primaries (3 cases). No MANECs were found 207 
in the small bowel or appendix.  208 
All neoplasms investigated showed 30% or more reactive cells for synaptophysin, while only 209 
90/160 cases showed significant reactivity for chromogranin-A. Thus, we based our 210 
identification of the NEC component on the synaptophysin positive, poorly differentiated 211 
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neuroendocrine part of the neoplasm (Figure 1A, 1B). Most MANECs (75.6%) had a NEC 212 
component in the 50% to 70% range (Table 1). Considering the NEC component, the large 213 
cell type (n=135, 84.4%) was more frequent compared to the small cell type. In the non-NEC 214 
component, conventional adenocarcinoma was the dominant histotype (n=105), followed by 215 
mucinous (n=17, 11 of which colorectal), signet ring cell (n=10, 8 of which gastric) and 216 
squamous cell carcinoma (n=5, 4 of which esophageal or cardio-esophageal). Fifty four 217 
(33.8%) tumors showed a collision pattern, 82 (51.2%) a purely combined pattern, and 24 218 
(15.0%) a mixed amphicrine and combined pattern. In collision neoplasms, the 219 
adenocarcinomatous component was usually overlying a deep, invasive NEC component. In 220 
combined neoplasms the two components were admixed without distinction between 221 
superficial and deep aspects (Figure 1A-1B) however the invasive tumor front (Figure 1C) 222 
was predominantly of NEC type with a pure NEC component in 71 (44.4%) cases, mixed 223 
NEC/non-NEC component in 79 (49.4%) cases and pure non-NEC carcinomatous component 224 
in 10 cases (6.2%) only. Angioinvasion was seen in all MANEC cases. Neoplastic emboli in 225 
vessels were prevalently of NEC or mixed NEC/non-NEC type. 226 
Nodal metastases (Figure 1D) were of pure NEC histotype in 35 (26.5%) and mixed NEC/non-227 
NEC in 97 (73.5%) cases. In distant metastases pure NEC histology was found in 6 (35.3%) 228 
cases, and mixed NEC/non-NEC histology in 11 cases (64.7%). Pure non-NEC component was 229 
not detected in metastases. 230 
 231 
Survival Analysis 232 
In the overall cohort, median OS was 13.2 months (95% CI 12.4-14.3) (Figure 2A). 233 
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Site: OS was significantly shorter in patients with colorectal tumors (median 12.2 months; 234 
95% CI 10.3-13.3) compared to patients with tumors in other digestive system sites: gastro-235 
esophageal or pancreato-biliary (median 17.3 months; 95% CI 13.3-19.9) (p=0.001) (Figure 236 
2B). 237 
Immunohistochemistry markers: The majority of IHC markers showed no statistical 238 
association with OS (Supplementary Table 1). Only CD117 (Table 2), evaluated in the NEC 239 
component, was associated with OS at univariable analysis (HR=1.59; 95% CI 1.13-2.24; 240 
p=0.008), although the association lost statistical significance at multivariable analysis 241 
(HR=1.42; 95% CI 0.99-2.04; P=0.06). Loss of MMR proteins (MLH1 and PMS2 in all cases) 242 
was found in 8/160 neoplasms with equal involvement of NEC and non-NEC components and 243 
no significant influence on OS (Supplementary table 1). Rb, p53, CD117, CDX2 and ALDH 244 
were significantly co-expressed in both NEC and non-NEC components (Supplementary Table 245 
3). The distribution of immunohistochemical markers in the NEC and non-NEC components is 246 
reported in Supplementary Table 1. 247 
Proliferation: A preliminary evaluation of the NEC component showed 55% to be an optimal 248 
prognostic cut-off for Ki67 index and 50 mitoses/10HPF to be optimal for MC 249 
(Supplementary Figure 1). Ki67 index turned out to be ≥55% in the large majority (82.5%) of 250 
cases, while MC was ≥50 in 30.6% of cases. On the other hand, in the non-NEC component 251 
Ki67 was ≥55% in 51.9% and MC was ≥50/10 HPF in 17.5% of cases. 252 
Patients with Ki67 index <55% in the NEC component (median 40.5 months; 95% CI 34.5-253 
53.2) had a significatively longer OS than those with Ki67 ≥55% (median 12.2 months; 95% CI 254 
11.1-13.2) p<0.0001. The latter showed a hazard ratio (HR) of 9.08 (95% CI 5.13-16.1) vs 255 
Ki67<55% (p<0.0001) after adjustment for tumor site, which retained high significance at 256 
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multivariable analysis (Figure 2c and Table 2). Patients with MC <50 mitoses/10HPF also had 257 
significatively longer OS (median 14.1; 95% CI 13.0-16.4) compared to those with ≥50 258 
mitoses/10 HPF (median 11.2 months; 95% CI 9.5-13.2; p=0.002), although with clearly lower 259 
HR (Table 2). In the non-NEC component, a Ki67index of ≥55% was associatewd with a tumor 260 
site-adjusted HR of 1.81; 95% CI 1.28-2.54 (p=0.0007) vs. <55%, which lost statistical 261 
significance at multivariable analysis, while a MC ≥50/10HPF lacked any significant difference 262 
compared to MC <50/10HPF. 263 
Stage: Patients with early stage (I-IIIA) tumor (24 cases) had longer OS (median 22.1 months; 264 
95% CI 12.8-36.4) compared to 119 patients with stage IIIB (median 12.7 months; 95% CI 265 
11.2-13.3) or 17 patients with stage IV disease (median 15.7 months; 95% CI 12.2-23.3), with 266 
a significant difference (p=0.003) between I-IIIA and IIIB+IV cases (Figure 2D). 267 
When an analysis of OS adjusted for tumor site was performed, OS was shown to be 268 
significantly associated with tumor stage, MANEC subtype (mixed amphicrine/combined 269 
versus collision), perineural infiltration, high grade budding (Figure 1 C) and NGS gene 270 
mutations, in addition to Ki67, MC and CD117 in the NEC component, and Ki67 only in the 271 
non-NEC component (Table 2). 272 
At multivariable analysis, only tumor site, Ki67 and MC in the NEC component and mutations 273 
were independently associated with OS (Table 2). Patients with gastro-esophageal tumors 274 
(HR=0.64; 95% CI 0.43-0.96; p=0.03) and those with pancreato-biliary tumors (HR=0.58; 95% 275 
CI 0.33-1.04; p=0.07) had significantly better survival compared to patients with colorectal 276 
MANECs. Patients with Ki67 ≥55% in the NEC component had a 7.83 fold increased risk of 277 
death (95% CI 4.17-14.7; p<0.0001) compared to patients with a Ki67 <55%, while patients 278 
with MC ≥50 mitoses/10 HPF had a 1.51 fold risk of death (95% CI 1.03-2.20, p=0.04). A 279 
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mutation in either KRAS or BRAF or TP53 genes (HR for any mutation 2.68; 95% CI 1.50-4.81; 280 
p=0.0009) was significantly associated with unfavorable outcome (Table 2). The risk was 281 
comparable KRAS mutations (HR 2.69; 95% CI 1.24-5.82; p=0.01) and TP53 mutations (HR 282 
2.90; 95% CI 1.48-5.68; p=0.002) (Footnote Table 2).  283 
DISCUSSION  284 
This study demonstrates that the prognosis of MANECs from digestive system is driven 285 
mostly by the NEC component with special reference to its Ki67 proliferative index. Ki67 286 
index of the NEC component has proven to be far superior to MC or, indeed, to any other 287 
prognostic parameter, either morphologic (prevalence of NEC versus non-NEC component, 288 
NEC small or large cell histology, histologic type), immunohistochemical (p53, Rb1, Bcl-2, 289 
p16, Cdx2, MMR deficiency, TTF1, ALDH, CD117,SSTR2A protein expression or proliferative 290 
index of the non-NEC component) or molecular (TP53 or KRAS or BRAF mutation). Of such 291 
parameters, only primary site, CD117 immunostaining of the NEC component, perineural 292 
infiltration, high grade budding and TP53 or KRAS mutations were associated with shorter OS 293 
at univariate analysis, while only site and mutations (as well the aforementioned NEC 294 
component Ki67 index)  retained prognostic value at multivariable analysis (Table 2). 295 
Accordingly, in the diagnostic work up of MANECs, besides identifying the NEC component 296 
histologically and immunohistochemically (by synaptophysin and chromogranin-A reactivity), 297 
evaluation should also focus on the quantitative assessment of Ki67 index in the 298 
neuroendocrine component. While proliferative rate has been widely shown to be an important 299 
diagnostic tool for neuroendocrine neoplasms, this study, has added new and interesting findings 300 
with regards to the importance of proliferation in MANECs as well. Indeed, as previously reported for 301 
pure NECs (Sorbye, et al. 2013) a Ki67 threshold of 55% also distinguishes between two 302 
different prognostic classes of MANECs with significant survival differences. These findings 303 
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parallel our previously published results on pure gastroenteropancreatic NECs (Milione, et al. 304 
2017), and show that the OS of MANECs with Ki67 ≥55% closely reproduces that of 305 
corresponding pure poorly differentiated NECs with Ki67 ≥55% (Type C NECs according to 306 
(Milione et al. 2017)(Fig 3b). Conversely, and perhaps more interestingly, with all the 307 
limitations of comparing two different studies, MANECs with Ki67 <55% showed better 308 
survival compared to pure poorly differentiated NECs with Ki67 between 21-55% (Type B 309 
NECs according to (Milione et al. 2017). 310 
Our findings parallel those of a large study on resected colorectal neoplasms, where survival 311 
outcomes of NECs were compared with those of patients with high-grade adenocarcinoma 312 
(Shafqat, et al. 2015): the results demonstrated that the median survival was significantly 313 
shorter (7.1 months) for patients with NECs compared with that of patients affected by high 314 
grade adenocarcinoma (36.0 months). Likewise the 5-year OS of patients with gastric NECs 315 
(38.7%) was poorer than that of patients with gastric adenocarcinoma (51.8%) (Xie, et al. 316 
2017). The frequent finding of the NEC component only at the invasive front of MANECs or in 317 
metastases, suggests that this component is mainly responsible for their aggressiveness. 318 
In our study we showed that the UICC/AJCC staging system developed for site corresponding 319 
carcinomas, was prognostically informative also for MANECs. Although most patients were 320 
diagnosed at an advanced stage (stage IIIB or IV), with severe prognosis, a small proportion 321 
(24 cases, 15%) of potentially curable patients (stage I to IIIA) was identified. As such, our 322 
data support the WHO recommendation of considering MANECs as ordinary carcinomas, 323 
providing evidence for the application of the relevant dedicated staging in real life pathology 324 
reporting. 325 
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The significant association of several molecular markers, including Rb, p16, p53 CDX2, 326 
CD117, ALDH and MMR that we found in both NEC and non-NEC components ,seems to 327 
confirm and to extend previous studies (Furlan et al. 2003; Furlan, et al. 2013; Jesinghaus et 328 
al. 2017; Kloppel 2017; Woischke et al. 2017). This finding suggests a possible common origin 329 
of the two MANEC components from a pluripotent cancer stem cell which undergoes 330 
divergent differentiation, during tumor progression. The mixed NEC/non-NEC pattern of 331 
growth we found in 73.5% of nodal and 64.7% of distant metastases may by itself support 332 
the proposed origin of the two components from a single, metastatic, bipotent clone, 333 
although the origin of some mixed metastases from cytologically mixed emboli cannot be 334 
excluded. Our finding of a greater  frequency MANECs in the colon and stomach, where 335 
ordinary carcinomas are also highly prevalent, coupled with the apparent lack of MANECs 336 
originating in the mesenteric small intestine and appendix, where conventional carcinomas 337 
rarely arise, suggests a MANEC histogenesis more akin to that of classical (adeno)carcinomas 338 
than to that of neuroendocrine tumors. 339 
In conclusion, this study of a large series of digestive system MANECs shows that the 340 
outcome of these neoplasms is mainly determined by their poorly differentiated 341 
neuroendocrine component and that the Ki67 proliferative index (above or below 55%) is 342 
the most important prognostic factor. 343 
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FIGURE LEGENDS 
Figure 1.Two adjacent sections of a combined MANEC illustrate the intimate 
admixture of the NEC and non-NEC components of the neoplasm. A: 
Hematoxylin/Eosin; B: Synaptophysin Immunohistochemistry. Both ×100; C: Invasive 
front of colonic MANEC showing exclusively a NEC component massively reactive 
for Synaptophysin. Note the associated high grade budding (arrows) ×100; D: 
Synaptophysin immunostained intestinal MANEC in lymph node metastases, 
massive in the left lymph node and sinusoidal only (arrow) in the right lymph node, 
both composed exclusively of NEC cells. ×100. E: NEC component of a MANEC with 
40% of Ki67 proliferative index. ×400; F: NEC component of a MANEC with 90% of 
Ki67 index ×400. 
 
Figure 2. Overall survival of the whole 160 MANECs population (A), of MANECs 
according to tumor site (B) or according to Ki67 proliferative index (C) or according to AJCC 
staging system (D). 
Figure 3. Comparison of overall survival according to Ki67 expression in the current study on 
MANECs compared to 112 pure poorly differentiated neuroendocrine carcinomas (Type B 
and C NECs from Milione et al. Neuroendocrinology 2017 Used by permission from S. Karger 
AG, Basel). 
Supplementary Figure 1. Overall survival based cut offs for Ki67 proliferative index or mitotic 
count in the NEC  component of the 160 MANECs. 
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Table 1. Main characteristics of patients with MANEC according to tumor site 
 
 
All Colorectal 
Gastro-
esophageal 
 Pancreato-
biliary 
P-value 
Total 160 92 44 24  
Sex      
Male 116 61 38 17  
Female 44 31 6 7 0.04 
Age      
<60 40 25 12 3  
60-69 55 31 14 10  
70+ 65 36 18 11 0.66 
Stage      
I/II (pN-) 11 3 3 5  
IIIA (pN-) 13 6 1 6  
IIIB (pN+) 119 74 34 11  
IV ( M+) 17 9 6 2 0.002 
MANEC sub-type      
Collision 54 35 12 7  
Combined 82 44 26 12  
Amphicrine/Combined 24 13 6 5 0.63 
NEC type      
Large cells 135 78 41 16  
Small cells 25 14 3 8 0.02 
NEC necrosis      
Absent 40 23 8 9  
Present 120 69 36 15 0.21 
% NEC component      
< 50%% 39 19 14 6  
50-60% 68 40 18 10  
                                         >60% 53 33 12 8 0.70 
Ki67 (NEC)      
<55% 28 13 7 8  
≥55% 132 79 37 16 0.10 
Ki67 (non NEC)      
<55% 77 47 17 13  
≥55% 83 45 27 11 0.34 
MC (NEC)      
<50/10HPF 111 62 32 17  
≥50/10HPF 49 30 12 7 0.81 
MC (non NEC)      
<50/10HPF 132 73 39 20  
≥50/10HPF 28 19 5 4 0.41 
Nerve infiltration      
Absent 20 12 4 4  
Present 106 63 28 15 0.69 
Angioinvasion      
Absent 23 14 6 3  
Present 137 78 38 21 1.00 
Budding      
Low 47 24 17 6  
Intermediate 47 33 8 6  
High 66 35 19 12 0.21 
Peritumoral lymphoid cells      
Absent 70 42 18 10  
Mild 64 32 18 14  
Moderate 23 16 7 0  
Page 22 of 28
Severe 3 2 1 0 0.19 
Intratumoral lymphoid cells      
Absent 74 42 22 10  
Mild 69 41 15 13  
Moderate 13 6 6 1  
Severe 4 3 1 0 0.61 
N+ (%NEC)      
Median (range) 70 (0-100) 70 (0-100) 70 (20-100) 90 (0-100)  
<100% (Mixed) 97 57 31 9  
100% (pure NEC) 35 23 8 4 0.61 
M+ (%NEC)      
Median (range) 85 (20-100) 90 (20-100) 55 (20-100) 88 (85-90)  
<100% (Mixed) 11 5 4 2  
100% (pure NEC) 6 4 2 0 0.80 
Molecular analysis      
Wild type 38 14 15 9  
KRAS mutated 12 11 1 0  
BRAF mutated 4 3 0 1  
TP53 mutated 17 9 8 0 0.004 
* Some immunohistochemical evaluations are missing for some patients;  
Ki67: Ki67 index; M+: Liver metastasis; MANEC: Mixed adenoneuroendocrine carcinomas; MC: Mitotic count; N+: 
Lymph node metastasis; NEC: neuroendocrine carcinoma;  
 Budding: single tumor cell or a cell cluster (buds) of up to 4 tumor cells, detected at the invasive tumor front; Low 
grade Budding:< 4 buds; Intermediate grade Budding: 5-10 buds; High grade budding: >10 buds 
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Table 2. Univariate and multivariable analysis for overall survival 
 
 Adjusted for site 
HR (95% CI) * 
P-value 
Multivariable 
2 
HR (95% CI) 
P-value 
Multivariable 
3
 
HR (95% CI) 
P-value 
Site       
Colorectal 1.00  1.00  1.00  
Gastroesophageal 0.73 (0.50-1.06) 0.10 0.61 (0.39-0.94) 0.02 0.64 (0.43-0.96) 0.03 
Pancreatobiliary 0.41 (0.25-0.67) 0.0004 0.54 (0.29-1.03) 0.06 0.58 (0.33-1.04) 0.07 
Stage       
I/II/IIIA (pN-) 1.00  1.00  1.00  
IIIB (pN+) 2.03 (1.20-3.42) 0.008 1.70 (0.90-3.22) 0.10 1.75 (0.95-3.23) 0.07 
IV ( M+) 1.59 (0.80-3.16) 0.19 1.08 (0.48-2.40) 0.86 1.09 (0.51-2.31) 0.83 
MANEC subtype       
Collision 1.00  1.00    
Combined 0.90 (0.63-1.28) 0.56 1.07 (0.72-1.61) 0.73 -  
Amphicrin/Combined 0.56 (0.33-0.96) 0.04 0.83 (0.45-1.53) 0.55 -  
NEC type       
Large cells 1.00  1.00    
Small cells 1.54 (0.97-2.43) 0.07 1.27(0.77-2.10) 0.35 -  
NEC component       
% NEC component (per 10%) 1.09 (0.96-1.22) 0.18 -  -  
Ki67 (≥55% vs. <55%) 9.08 (5.13-16.1) <0.0001 8.92 (3.96-20.1) <0.0001 7.83 (4.17-14.7) <0.0001 
MC (≥50/10HPF vs. <50/10HPF) 1.81 (1.28-2.58) 0.0009 1.53 (1.03-2.28) 0.04 1.51 (1.03-2.20) 0.04 
p53 (≥30% vs. <30%) 1.10 (0.78-1.56) 0.58 -  -  
CD117 (positive vs. negative) 1.59 (1.13-2.24) 0.008 1.45 (0.98-2.15) 0.06 1.42 (0.99-2.04) 0.06 
SSTR2a (positive vs. negative) 1.21 (0.87-1.68) 0.25 -    
Non-NEC component       
Ki67 (≥55% vs. <55%) 1.81 (1.28-2.54) 0.0007 1.29 (0.87-1.92) 0.20 -  
MC (≥50/10HPF vs. <50/10HPF) 1.39 (0.91-2.11) 0.13 -  -  
Nerve infiltration       
Present vs. absent 3.20 (1.77-5.77) 0.0001 0.88 (0.42-1.82) 0.72 -  
Angioinvasion       
Present vs. absent 0.85 (0.54-1.33) 0.47 -  -  
Budding       
Absent 1.00  1.00    
Mild/moderate 0.82 (0.53-1.27) 0.37 1.29 (0.72-2.28) 0.39 -  
Severe 1.97 (1.31-2.96) 0.001 1.13 (0.65-1.96) 0.67 -  
Molecular Analysis**       
Wild type 1.00  1.00  1.00  
Mutated 2.36 (1.41-3.97) 0.001 2.22 (1.19-4.15) 0.01 2.68 (1.50-4.81) 0.0009 
 
CD117: tyrosine-protein kinase Kit; Ki67: Ki67 index; M+: Liver metastases; MANEC: Mixed adeno-neuroendocrine 
carcinoma; MC: Mitotic count; N+: Lymph node metastases; NEC: neuroendocrine carcinoma; SSTR2a: somatostatin 
receptor 2a. 
 
Multivariable model 2 includes all factors associated with overall survival after single adjustment for tumor site; 
Multivariable model 3 retains only variables showing an association (P<0.10) with overall survival. 
 
** Multivariable risk estimates for single gene mutations from alternative model 3: KRAS mutated [n=12; HR=2.69 
(1.24-5.82); P=0.01]; BRAF mutated [n=4; HR=1.81 (0.51-6.39); P=0.36]; TP53 mutated [n=17; HR=2.90 (1.48-5.68); 
P=0.002]. 
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Figure 3. Overall survival according to Ki67 expression in MANEC and poorly differentiated NEC 
 
A 
 
B 
 
At risk       At risk       
NEC 180 88 36 15 10 8 PD NEC Ki67<55% 49 41 21 7 4 2 
       PD NEC Ki67≥55% 131 47 15 8 6 6 
MANEC 160 97 31 16 9 6 MANEC Ki67<55% 28 28 24 13 7 6 
       MANEC Ki67≥55% 132 69 7 3 2 0 
  
 Overall Survival (95% Confidence Intervals) 
 12-month 24-month 36-month 48-month 60-month Median OS 
PD NEC 48.9 (41.4-55.9) 20.0 (14.5-26.1)   8.3 (  4.9-12.9)   5.6 (  2.8-  9.6)   4.4 (  2.1-  8.2) 11.0 (  8.4-13.0) 
MANEC 61.1 (53.1-68.2) 20.8 (14.8-27.5) 12.3 (  7.7-18.2)   6.9 (  3.5-12.0)   4.6 (  1.9-  9.1) 13.2 (12.4-14.3) 
PD NEC Ki67<55% 83.7 (70.0-91.5) 42.9 (28.9-56.1) 14.3 (  6.3-25.5)   8.2 (  2.6-17.9)   4.1 (  0.8-12.3) 20.0 (16.9-25.0) 
PD NEC Ki67≥55% 35.9 (27.8-44.0) 11.5 (  6.7-17.6)   6.1 (  2.9-11.1)   4.6 (  1.9-  9.1)   4.6 (  1.9-  9.1)   7.6 (  5.5-10.0) 
MANEC Ki67<55% 100 96.2 (76.1-99.5) 62.0 (39.6-78.1) 33.4 (15.2-52.8) 28.6 (11.9-48.0) 40.5 (34.5-53.2) 
MANEC Ki67≥55% 52.9 (44.0-61.0)   5.4 (  2.4-10.2)   2.3 (  0.6-  6.0)   1.5 (  0.3-  4.9) - 12.2 (11.1-13.2) 
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